Funding
← Back to your selection

Invus

Activity from announced rounds

Activity in this selectionOct 17, 2026 · Jul 20, 2026

Invus is the investment-firm name used by Encoded Therapeutics and in LifeMine transaction-counsel coverage.

Recorded funding activity

Encoded develops precision gene therapies for neurological disorders. LifeMine uses fungal genomes for drug discovery, while City develops RNA-interference medicines. The records identify different therapeutic approaches without substituting an unnamed parent or fund.

Sources
Rounds participated in
3
Confirmed lead rounds
0
1 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$673M
3 disclosed · full round size, not this investor’s share

By stage

Series B1
Series C+1
Undisclosed1

By primary sector

Biotech3

By country

United States3

Rounds

3 in this selection
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B
Participant
Encoded Therapeutics Inc.

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

$275MSeries F
Participant
LifeMine Therapeutics

Develops fungal genome-derived therapeutics for organ transplant rejection

$263MSeries D+Series E
Role not disclosed